Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment by Gregory W. Charville, Sukhmani K. Padda, Richard K. Sibley, Ajithkumar Puthillath, Paul Y. Kwo

“…We discuss the case of a 26-year-old female with a history of ROS1-rearranged lung adenocarcinoma, undergoing treatment with the tyrosine kinase inhibitor crizotinib, who presented to our hospital with abdominal pain and scleral icterus. …”
Get full text

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations by Abhimanyu Tushir, Israh Akhtar, Anjali Seth

“…The majority of these co-occurring alterations were detected in samples collected from patients with resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. …”
Get full text

Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature by Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick

“…These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. …”
Get full text

The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing by Kai Kou, Xiaodong Sun, Guangyao Tian, Yao Zhi, Zhongqi Fan, Guoyue Lv

“…In this process, the dysfunction of monocyte and macrophage is reflected in the downregulation of HLA-DR and upregulation of MER tyrosine kinase (MERTK), which weakens the antigen presentation function and reduces the secretion of inflammatory cytokines. …”
Get full text

Busting the Breast Cancer with AstraZeneca’s Gefitinib by S. Chemmalar, A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan, Md Zuki Abu Bakar Zakaria

“…Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast cancer and is supported by a multiplicity of experiments. …”
Get full text

PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism by Hongyu Chu, Yuezhan Shan, Chengwei Jiang, Yumin Zhong, Zijing Liu, Xuedong Fang, Zhaoying Yang

“…Notably, PNMA1 has emerged as a promising therapeutic target for tyrosine kinase inhibitors, as confirmed by reduced IC50 values and molecular docking. …”
Get full text

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia by Anthony A. Oyekunle, Rahman A. Bolarinwa, Adesola T. Oyelese, Lateef Salawu, Muheez A. Durosinmi

“…Objective. The tyrosine kinase inhibitors have markedly changed the disease course for patients with Ph+ and/or BCR-ABL1+ chronic myeloid leukemia (CML). …”
Get full text

Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024) by Yeow Tee Goh, Yvonne Loh, Esther Chan, Yuh Shan Lee, Venkata Sreekanth Sampath, Daryl Tan, Shin Yeu Ong, Chandramouli Nagarajan

“…Due to the superior efficacy of targeted agents (Bruton's tyrosine kinase inhibitors [BTKis] and B-cell lymphoma 2 inhibitors [BCL2is]), sthese are favoured over standard chemotherapy or chemotherapy-immunotherapy, especially for patients with del(17p) or TP53 mutation, and less fit patients. …”
Get full text

Current preeclampsia prediction model and biomarker by Anak Agung Ngurah Jaya Kusuma

“…Additionally, biomarkers like mean arterial pressure (MAP), UtA-PI, and the ratio of soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1/PlGF) are employed to improve predictive accuracy. …”
Get full text

Rare skin adverse reactions induced by osimertinib: a case report and literature review by Ye Zhang, Mingzhu Ling, Min Wang, Ye Chen, Liting Zhang

“…Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. …”
Get full text

A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified 
Lung Squamous Cell Carcinoma and Literature Review by Yalan LIU, Peng CHEN, Xinfu LIU

“…At present, some selective tyrosine kinase inhibitors (TKIs) of MET has been approved for non-small cell lung cancer with MET gene 14 exon skipping mutation, such as Glumetinib, Savolitinib, Tepotinib, Capmatinib, etc. …”
Get full text

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation by B. Uz, O. Bektas, E. Eliacik, H. Goker, Y. Erbilgin, M. Sayitoglu, N. Sayinalp, S. Aksu, Y. Buyukasik, O. Ozcebe, I. C. Haznedaroglu

“…The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. …”
Get full text

Angiogenic Factors and Renal Disease in Pregnancy by Julie S. Rhee, Brett C. Young, Sarosh Rana

“…Prior studies show that there is an angiogenic factor imbalance with elevated levels of antiangiogenic proteins soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) and reduced levels of the proangiogenic protein, placental growth factor (PlGF) in women with preeclampsia. …”
Get full text

Flt3/Flt3L Participates in the Process of Regulating Dendritic Cells and Regulatory T Cells in DSS-Induced Colitis by Jing-Wei Mao, Yu-Shuang Huang, Hai-Ying Tang, Jian Bi, Yan-Fei Liu, Ying-De Wang

“…Recent research showed that Fms-like tyrosine kinase 3 (Flt3) and Flt3 ligand (Flt3L) were involved in the process of DCs regulating T-regs. …”
Get full text

Proteomic Profiling of Ex Vivo Expanded CD34-Positive Haematopoetic Cells Derived from Umbilical Cord Blood by Heiner Falkenberg, Teja Falk Radke, Gesine Kögler, Kai Stühler

“…In the presented publications, CD34-positive cells were isolated from cord blood and expanded for up to 7 days in media supplemented with stem cell factor (SCF), thrombopoietin (THPO), interleukin 6 (IL-6), and fms-related tyrosine kinase 3 ligand (FLT3lg). At days 3 and 7, expanded cells were harvested and analyzed by flow cytometry and quantitative proteomics. 2970 proteins were identified, whereof proteomic analysis showed 440 proteins significantly changed in abundance during ex vivo expansion. …”
Get full text

Clinical advances in antibody-drug conjugates for hematological malignancies by TANG Sijie, MI Jianqing

“…Additionally, ADCs targeting different antigens such as CD123, CD19, CD20, receptor tyrosine kinase-like orphan receptor 1 (ROR1), and CD38 are undergoing clinical studies. …”
Get full text

Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC by Jin Lei, Hongyuan Dai, Ya Zhang, Guangling Ou, Zhi Peng Liang, Yinying Lu, Haiyang Li

“…Patients in the primary group had significantly shorter median OS than those in the secondary group (9.0 months vs 23.0 months, p  < 0.001). Compared with tyrosine kinase inhibitor (TKI) monotherapy, the use of TKI plus PD-1 inhibitor combination therapy as second-line treatment conferred a longer median PFS (6.0 vs 10.0 months, p  < 0.001) and OS (13.0 vs 22.0 months, p  < 0.001). …”
Get full text

GILT stabilizes cofilin to promote the metastasis of prostate cancer by Dunsheng Han, Zhiming Wu, Cong Zhang, Ziwei Wei, Fan Chao, Xuefeng Xie, Jinke Liu, Yufeng Song, Xiaoming Song, Dingchang Shao, Shiyu Wang, Guoxiong Xu, Gang Chen

“…Mechanistically, GILT stabilized the cofilin protein by competitively binding to cofilin with Src family tyrosine kinase (SRC), inhibiting SRC-mediated tyrosine phosphorylation of cofilin, thereby suppressing the ubiquitination pathway degradation of cofilin. …”
Get full text

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. by Karsten Jürchott, Ralf-Jürgen Kuban, Till Krech, Nils Blüthgen, Ulrike Stein, Wolfgang Walther, Christian Friese, Szymon M Kiełbasa, Ute Ungethüm, Per Lund, Thomas Knösel, Wolfgang Kemmner, Markus Morkel, Johannes Fritzmann, Peter M Schlag, Walter Birchmeier, Tammo Krueger, Silke Sperling, Christine Sers, Hans-Dieter Royer, Hanspeter Herzel, Reinhold Schäfer

“…To identify regulators of transcriptome alterations, we used an integrated approach combining transcriptional profiling of colorectal cancer cell lines treated with inhibitors targeting the receptor tyrosine kinase (RTK)/RAS/mitogen-activated protein kinase pathway, computational prediction of regulatory elements in promoters of co-regulated genes, chromatin-based and functional cellular assays. …”
Get full text

Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma by Ikhwan Rinaldi, Abdul Muthalib, Januar Widodo Sutandar, Hendro Adi Kuncoro, Bambang Irawan Harsono, Nelly Susanto, Tjondro Setiawan, Kevin Winston, Idham Rafly Dewantara, Ihya Fakhrurizal Amin, Yuli Maulidiya Shufiyani

“…In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. …”
Get full text